{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-25-000012","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.604089+00:00","generated_at":"2026-05-25T11:33:38.033072+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zymeworks reports $122.7M net loss for 2024; Ziihera approval drives $25M milestone","bullets":["Revenue $76.3M in 2024 (vs $76.0M in 2023); net loss $122.7M vs $118.7M loss prior year.","Cash resources $324.2M at Dec 31, 2024; projected runway into 2H-2027 with anticipated regulatory milestones.","Ziihera (zanidatamab) FDA approved for HER2+ BTC in Nov 2024; initial net sales $1.1M; $25M milestone earned from Jazz.","Phase 1 studies initiated for ZW191 and ZW171; IND for ZW251 accelerated to mid-2025; ZW220 preparations paused.","Non-cash impairment charge of $17.3M for discontinuation of zanidatamab zovodotin; $14M milestone from GSK in Jan 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-25-000012","json":"https://secwatch.observer/filing/0001937653-25-000012.json","markdown":"https://secwatch.observer/filing/0001937653-25-000012.md","text":"https://secwatch.observer/filing/0001937653-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765325000012/0001937653-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765325000012/zyme-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T11:33:38.033072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}